Toward predictive models for drug-induced liver injury in humans: Are we there yet?

Biomarkers in Medicine

Volumn 8, Issue 2, 2014, Pages 201-213

  Chen, Minjun ^a   Bisgin, Halil ^a   Tong, Lillian ^a,b   Hong, Huixiao ^a   Fang, Hong ^a   Borlak, Jürgen ^c   Tong, Weida ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b California Institute of Technology   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

biomarker; drug label; drug safety; drug induced liver injury; predictive model

Indexed keywords

ANIMALS; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TOXICOGENETICS;

EID: 84894372252     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.146     Document Type: Review

References (85)

1. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137(12), 947-954 (2002).
2. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 52(6), 2065-2076 (2010).
3. Zimmerman HJ. Drug-induced liver disease. Clin. Liver Dis. 4(1), 73-96, vi (2000).
4. Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 47(6), 1813-1815 (2008).
5. Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. J. Hepatol. 26(Suppl. 2), 26-36 (1997).
6. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA 287(17), 2273-2275 (2002).
7. Fung M, Anna T, Kathy M, Wu J, Ken H, Edmundo M. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999. Drug Information Journal 35(1), 293-317 (2001).
8. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-Approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 16(15-16), 697-703 (2011).
9. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4(6), 489-499 (2005).
10. Olson H, Betton G, Robinson D et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32(1), 56-67 (2000).
11. Xu JJ, Diaz D, OBrien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact. 150(1), 115-128 (2004).
12. Kaplowitz N, DeLeve LD. Drug-Induced Liver Disease (Third Edition). Academic Press, MA, USA (2013).
13. Przybylak KR, Cronin MT. In silico models for drug-induced liver injury - current status. Expert Opin. Drug Metab. Toxicol. 8(2), 201-217 (2012).
14. Corsini A, Ganey P, Ju C et al. Current challenges and controversies in drug-induced liver injury. Drug Saf. 35(12), 1099-1117 (2012).
15. Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity - two villains or one? J. Pharmacol. Exp. Ther. 332(3), 692-697 (2010).
16. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf. 30(4), 277-294 (2007).
17. Suzuki A, Andrade RJ, Bjornsson E et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 33(6), 503-522 (2010).
18. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105(1), 97-105 (2008).
19. Sakatis MZ, Reese MJ, Harrell AW et al. Preclinical Strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for > 200 compounds. Chem. Res. Toxicol. 25(10), 2067-2082 (2012).
20. Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury - current status. Crit. Rev. Toxicol. 41(9), 723-739 (2011).
21. Hewitt M, Enoch SJ, Madden JC, Przybylak KR, Cronin MTD. Hepatotoxicity: a scheme for generating chemical categories for read-Across, structural alerts and insights into mechanism (s) of action. Crit. Rev. Toxicol. 43(7), 537-558 (2013).
22. Egan WJ, Zlokarnik G, Grootenhuis PDJ. In silico prediction of drug safety: despite progress there is abundant room for improvement. Drug Discov. Today Technol. 1(4), 381-387 (2004).
23. Greene N. Computer systems for the prediction of toxicity: an update. Adv. Drug Deliv. Rev. 54(3), 417-431 (2002).
24. Stepan AF, Walker DP, Bauman J et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 24(9), 1345-1410 (2011).
25. Marchant CA, Fisk L, Note RR, Patel ML, Suarez D. An expert system approach to the assessment of hepatotoxic potential. Chem. Biodivers. 6(11), 2107-2114 (2009).
26. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ. Developing structure-Activity relationships for the prediction of hepatotoxicity. Chem. Res. Toxicol. 23(7), 1215-1222 (2010).
27. Cheng A, Dixon SL. In silico models for the prediction of dose-dependent human hepatotoxicity. J. Comput. Aided Mol. Des. 17(12), 811-823 (2003).
28. Cruz-Monteagudo M, Cordeiro MN, Borges F. Computational chemistry approach for the early detection of drug-induced idiosyncratic liver toxicity. J. Comput. Chem. 29(4), 533-549 (2008).
29. Matthews EJ, Ursem CJ, Kruhlak NL et al. Identification of structure-Activity relationships for adverse effects of pharmaceuticals in humans: part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. Regul. Toxicol. Pharmacol. 54(1), 23-42 (2009).
30. Rodgers AD, Zhu H, Fourches D, Rusyn I, Tropsha A. Modeling liver-related adverse effects of drugs using knearestneighbor quantitative structure-Activity relationship method. Chem. Res. Toxicol. 23(4), 724-732 (2010).
31. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem. Res. Toxicol. 23(1), 171-183 (2010).
32. Liew CY, Lim YC, Yap CW. Mixed learning algorithms and features ensemble in hepatotoxicity prediction. J. Comput. Aided Mol. Des. 25(9), 855-871 (2011).
33. Ekins S, Williams AJ, Xu JJ. A predictive ligand-based Bayesian model for human drug induced liver injury. Drug Metab. Dispos. 38(12), 2302-2308 (2010).
34. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation - drug induced liver injury prediction system (DILIps). PLoS Comput. Biol. 7(12), e1002310 (2011).
35. Chen M, Hong H, Fang H et al. Quantitative structure-Activity relationship models for predicting drug-induced liver injury based on FDA-Approved drug labeling annotation and using a large collection of drugs. Toxicol. Sci. 136(1), 242-249 (2013).
36. Tropsha A, Golbraikh A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr. Pharm. Des. 13(34), 3494-3504 (2007).
37. Tong W, Hong H, Xie Q, Shi L, Fang H, Perkins R. Assessing QSAR limitations - a regulatory perspective. Curr. Comput. Aided Drug Des. 1(2), 195-205 (2005).
38. Tong W, Xie Q, Hong H et al. Using decision forest to classify prostate cancer samples on the basis of SELDI-TOF MS data: assessing chance correlation and prediction confidence. Environ. Health Perspect. 112(16), 1622-1627 (2004).
39. Tolosa L, Pinto S, Donato MT et al. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol. Sci. 127(1), 187-198 (2012).
40. Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne-Sanchez A. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol. Sci. 129(2), 332-345 (2012).
41. OBrien PJ, Irwin W, Diaz D et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80(9), 580-604 (2006).
42. Khetani SR, Kanchagar C, Ukairo O et al. The use of micropatterned co-cultures to detect compounds that cause drug induced liver injury in humans. Toxicol. Sci. 132(1), 107-117 (2013).
43. Persson M, Lye AF, Mow T, Hornberg JJ. A high content screening assay to predict human drug-induced liver injury during drug discovery. J. Pharmacol. Toxicol. Methods 68(3), 302-313 (2013).
44. Usui T, Mise M, Hashizume T, Yabuki M, Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos. 37(12), 2383-2392 (2009).
45. Nakayama S, Atsumi R, Takakusa H et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 37(9), 1970-1977 (2009).
46. Sakurai A, Kurata A, Onishi Y, Hirano H, Ishikawa T. Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis ofdrugs inhibiting the human bile salt export pump. Expert Opin. Drug Saf. 6(1), 71-86 (2007).
47. Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45(5), 511-542 (2006).
48. Poulin P, Jones RD, Jones HM et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J. Pharm. Sci. 100(10), 4127-4157 (2011).
49. Afshari CA, Hamadeh HK, Bushel PR. The evolution of bioinformatics in toxicology: advancing toxicogenomics. Toxicol. Sci. 120(Suppl. 1), S225-S237 (2011).
50. Shi W, Bessarabova M, Dosymbekov D et al. Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes. Pharmacogenomics J. 10(4), 310-323 (2010).
51. Chen M, Zhang M, Borlak J, Tong W. A decade of toxicogenomic research and its contribution to toxicological science. Toxicol. Sci. 130(2), 217-228 (2012).
52. Uehara T, Ono A, Maruyama T et al. The Japanese toxicogenomics project: application of toxicogenomics. Mol. Nutr. Food Res. 54(2), 218-227 (2010).
53. Ganter B, Snyder RD, Halbert DN, Lee MD. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database. Pharmacogenomics 7(7), 1025-1044 (2006).
54. Cha HJ, Ko M-J, Ahn S-M et al. Identification of classifier genes for hepatotoxicity prediction in non steroidalanti inflammatory drugs. Mol. Cell. Toxicol. 6(3), 247-253 (2010).
55. Zhang M, Chen M, Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans? Chem. Res. Toxicol. 25(1), 122-129 (2012).
56. Low Y, Uehara T, Minowa Y et al. Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. Chem. Res. Toxicol. 24(8), 1251-1262 (2011).
57. Beger RD, Sun J, Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 243(2), 154-166 (2010).
58. Schnackenberg LK, Chen M, Sun J et al. Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicol. Appl. Pharmacol. 235(1), 25-32 (2009).
59. Ebbels TMD, Keun HC, Beckonert OP et al. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J. Proteome Res. 6(11), 4407-4422 (2007).
60. Wang K, Zhang S, Marzolf B et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl Acad. Sci. USA 106(11), 4402-4407 (2009).
61. Grant LM, Rockey DC. Drug-induced liver injury. Curr. Opin. Gastroenterol. 28(3), 198-202 (2012).
62. Starkey Lewis PJ, Dear J, Platt V et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54(5), 1767-1776 (2011).
63. Rusyn I, Sedykh A, Low Y, Guyton KZ, Tropsha A. Predictive modeling of chemical hazard by integrating numerical descriptors of chemical structures and short-term toxicity assay data. Toxicol. Sci. 127(1), 1-9 (2012).
64. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58(1), 388-396 (2013).
65. Zhu X, Sedykh A, Liu S. Hybrid in silico models for drug-induced liver injury using chemical descriptors and in vitro cell-imaging information. J. Appl. Toxicol. doi:10.1002/ jat.2879 (2013) (Epub ahead of print).
66. Gevaert O, De Smet F, Timmerman D, Moreau Y, De Moor B. Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks. Bioinformatics 22(14), e184-e190 (2006).
67. Chen M, Shi L, Kelly R, Perkins R, Fang H, Tong W. Selecting a single model or combining multiple models for microarray-based classifier development? - A comparative analysis based on large and diverse datasets generated from the MAQC-II project. BMC Bioinformatics 12(Suppl. 10), S3 (2011).
68. Cosgrove BD, King BM, Hasan MA et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-Associated idiosyncratic drug hepatotoxicity. Toxicol. Appl. Pharmacol. 237(3), 317-330 (2009).
69. Liss G, Rattan S, Lewis JH. Predicting and preventing acute drug-induced liver injury: whats new in 2010? Expert Opin. Drug Metab. Toxicol. 6(9), 1047-1061 (2010).
70. Urban TJ, Shen Y, Stolz A et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet. Genomics 22(11), 784 (2012).
71. Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics 13(7), 735-738 (2012).
72. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology 52(2), 748-761 (2010).
73. Kia R, Sison RLC, Heslop J et al. Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br. J. Clin. Pharmacol. 75(4), 885-896 (2013).
74. Huh D, Hamilton GA, Ingber DE. From 3D cell culture to organs-on-chips. Trends Cell Biol. 21(12), 745-754 (2011).
75. Hill A, Mesens N, Steemans M, Xu JJ, Aleo MD. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. Drug Metab. Rev. 44(1), 127-140 (2012).
76. Dorner M, Horwitz JA, Robbins JB et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 474(7350), 208-211 (2011).
77. Soldatow VY, LeCluyse EL, Griffith LG, Rusyn I. In vitro models for liver toxicity testing. Toxicol. Res. 2(1), 23-39 (2013).
78. Rockey DC, Seeff LB, Rochon J et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 51(6), 2117-2126 (2010).
79. Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. Hepatology 57(3), 873-874 (2013).
80. Chen M, Zhang J, Wang Y et al. Liver Toxicity Knowledge Base (LTKB) - a systems approach to a complex endpoint. Clin. Pharmacol. Ther. 95(5), 409-412 (2013).
81. Bisgin H, Liu Z, Fang H, Xu X, Tong W. Mining FDA drug labels using an unsupervised learning technique-topic modeling. BMC Bioinformatics 12(Suppl. 10), S11 (2011).
82. Wang Y, Lin Z, Liu Z et al. A unifying ontology to integrate histological and clinical observations for drug-induced liver injury. Am. J. Pathol. 182(4), 1180-1187 (2013).
83. Thomas CE, Will Y. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery. Expert Opin. Drug Discov. 7(2), 109-122 (2012).
84. Zimmerman HJ. Hepatotoxicity: the Adverse Effects of Drugs and Other Chemicals on the Liver. Lippincott, Williams & Wilkins, PA, USA (1999).
85. Guo JJ, Wigle PR, Lammers K, Vu O. Comparison of potentially hepatotoxic drugs among major US drug compendia. Res. Social Adm. Pharm. 1(3), 460-479 (2005).